{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T04:13:33Z","timestamp":1741925613702,"version":"3.38.0"},"reference-count":13,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"unspecified","delay-in-days":71,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Pall Supp Care"],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:title>Abstract<\/jats:title>\n\t  <jats:sec id=\"S147895152500001X_sec1a\">\n\t    <jats:title>Objectives<\/jats:title>\n\t    <jats:p>Naldemedine is a peripherally acting \u03bc-opioid receptor antagonist used to treat opioid-induced constipation. As this drug does not cross the blood\u2013brain barrier, it is believed that patients without brain metastases do not experience opioid withdrawal symptoms.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S147895152500001X_sec2b\" sec-type=\"methods\">\n\t    <jats:title>Methods<\/jats:title>\n\t    <jats:p>Here, we experienced a case in which a cancer patient without brain metastasis presented with anxiety and restlessness that was severe enough to interfere with daily life. The patient was diagnosed with naldemedine-induced opioid withdrawal syndrome.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S147895152500001X_sec3c\" sec-type=\"results\">\n\t    <jats:title>Results<\/jats:title>\n\t    <jats:p>The patient was a 66-year-old male with liver cancer metastasizing to the chest wall, but without brain metastasis. Oxycodone was started at 10 mg\/day 2 months prior to his visit to our department to treat pain related to the chest wall metastasis, and was increased to 100 mg\/day 1 month later and maintained at that dose. Naldemedine was administered as a countermeasure against opioid-induced constipation. The patient developed anxiety and restlessness 10 days prior to his initial visit to our department.\n<\/jats:p>\n\t    <jats:p>After detailed examination, naldemedine-related opiod withdrawal syndrome was suspected on the basis of anxiety, agitation, and episodes of sudden onset sweating, and these symptoms disappeared within 2 days after the discontinuation of naldemedine, with no recurrence observed thereafter. In addition, head MRI revealed no brain metastasis.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S147895152500001X_sec4d\">\n\t    <jats:title>Significance of the results<\/jats:title>\n\t    <jats:p>Even in patients without brain metastasis, naldemedine can induce opioid withdrawal symptoms, so caution is required with patients receiving this drug. In addition, when psychiatric symptoms are pronounced, as in this case, withdrawal symptoms may be underdiagnosed.<\/jats:p>\n\t  <\/jats:sec>","DOI":"10.1017\/s147895152500001x","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T08:34:30Z","timestamp":1741854870000},"update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":0,"title":["Opioid withdrawal syndrome induced by naldemedine administration in a cancer patient without brain metastasis"],"prefix":"10.1017","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-1284","authenticated-orcid":false,"given":"Mayumi","family":"Ishida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kojun","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isamu","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nozomu","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izumi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2949-2734","authenticated-orcid":false,"given":"Hideki","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"S147895152500001X_ref2","doi-asserted-by":"publisher","DOI":"10.1017\/S1478951521001917"},{"key":"S147895152500001X_ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s005200050281"},{"key":"S147895152500001X_ref13","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001174"},{"key":"S147895152500001X_ref6","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12862"},{"key":"S147895152500001X_ref11","doi-asserted-by":"publisher","DOI":"10.1017\/S1478951523000858"},{"key":"S147895152500001X_ref9","article-title":"Real-world evidence for the safety and effectiveness of naldemedine in the management of opioid-induced constipation in patients with cancer pain: Post-hoc subgroup analysis of post-marketing surveillance in Japan","volume":"15","author":"Naya","year":"2023","journal-title":"Cureus"},{"key":"S147895152500001X_ref3","doi-asserted-by":"publisher","DOI":"10.1017\/S147895152200044X"},{"key":"S147895152500001X_ref10","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000527"},{"key":"S147895152500001X_ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-019-0686-6"},{"key":"S147895152500001X_ref1","unstructured":"Food and Drug Administration (2017) Drugs@FDA: FDA-Approved Drugs. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/208854s002lbl.pdf (accessed 26 September 2024)."},{"key":"S147895152500001X_ref4","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.3098-19"},{"key":"S147895152500001X_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30207-1"},{"key":"S147895152500001X_ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.0853"}],"container-title":["Palliative and Supportive Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S147895152500001X","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T08:34:33Z","timestamp":1741854873000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S147895152500001X\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":13,"alternative-id":["S147895152500001X"],"URL":"https:\/\/doi.org\/10.1017\/s147895152500001x","relation":{},"ISSN":["1478-9515","1478-9523"],"issn-type":[{"value":"1478-9515","type":"print"},{"value":"1478-9523","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"\u00a9 The Author(s), 2025. Published by Cambridge University Press.","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http:\/\/creativecommons.org\/licenses\/by\/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"e64"}}